Valuation: ALLOVIRPAR

Market Cap 49.21M 42.48M 39.86M 36.3M 68.26M 4.71B 69.21M 467M 183M 2.36B 185M 181M 7.84B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -59.63M -55.95M -50.96M -95.82M -6.6B -97.14M -656M -257M -3.31B -259M -254M -11.01B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-2.94%
Current month-59.63%
Current year-59.63%
3 years 3.91
Extreme 3.9116
86.25
5 years 3.91
Extreme 3.9116
607.43
10 years 3.91
Extreme 3.9116
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -164M -154M -140M -264M -18.21B -268M -1.81B -708M -9.12B -715M -699M -30.34B -58.77M -50.74M -47.6M -43.35M -81.52M -5.62B -82.65M -558M -219M -2.82B -221M -216M -9.36B
Net Debt -157M -135M -127M -115M -217M -14.96B -220M -1.49B -582M -7.5B -588M -575M -24.94B -118M -102M -95.8M -87.26M -164M -11.31B -166M -1.12B -440M -5.67B -444M -434M -18.85B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change Volume
26-08-17 US$3.960 -2.94% 30,097
26-08-14 US$4.080 +5.15% 28,091
26-08-13 US$3.880 -1.52% 56,524
26-08-12 US$3.940 -0.76% 62,195
26-08-11 US$3.970 +0.76% 27,605
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock